ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Cialis (tadalafil) by Year
Cialis (tadalafil) — Outside U.S. revenue ($M) [legacy] ($M)
Eli Lilly Cialis (tadalafil): $355M in FY2023, down 35.6% from a year earlier. That is the lowest of the 8 years on record here. No newer figure appears in the documents we track.
Latest, FY2023
355
Period ended Dec 31, 2023
Change on a year earlier
-35.6%
552 in FY2022
History
8 years
Since FY2016
Sources
6
Documents cited below
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-21) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cialis (tadalafil) — Outside U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 355 | -35.6% | Form 10-K (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 552 | -22.0% | Form 10-K (filed 2024-02-21) ↗ |
| FY2021 | Dec 31, 2021 | 708 | +29.8% | Form 10-K (filed 2024-02-21) ↗ |
| FY2020 | Dec 31, 2020 | 545 | -17.2% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 659 | -8.8% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 723 | -25.1% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 965 | -3.8% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 1,002 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cialis (tadalafil) ($M), annual FY2016–FY2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-cialis-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.